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Brefeldin A is a macrolide compound that interferes with the secretory pathway and also affects protein synthesis in mammalian cells. As a
result, this antibiotic impedes the maturation of viral glycoproteins of enveloped viruses and viral genome replication in several virus species. In
the present work, we show that translation of subgenomic mRNA from Sindbis virus, which in contrast to cellular translation is resistant to
brefeldin A after prolonged treatment. The phosphorylation of eIF2α as a result of brefeldin A treatment correlates with the inhibition of cellular
translation, while late viral protein synthesis is resistant to this phosphorylation. The effect of brefeldin A on Sindbis virus replication was also
examined using a Sindbis virus replicon. Although brefeldin A delayed viral RNA synthesis, translation by non-replicative viral RNAs was not
affected, reinforcing the idea that brefeldin A delays viral RNA replication, but does not directly affect Sindbis virus protein synthesis.
© 2007 Elsevier Inc. All rights reserved.Keywords: Brefeldin A; Sindbis virus; Cellular translation; Viral protein synthesis; Sindbis virus replicationSindbis virus (Mirazimi et al., 1996) is the prototype member
of the Alphavirus genus of the Togaviridae family. The genome,
a positive-strand non-segmented RNA of almost 12 kb, consists
of two open reading frames: the first two-thirds encode non-
structural proteins (nsPs), while the remaining third encodes
structural proteins (Frolov, 2004; Strauss and Strauss, 1994). The
genomic 49S RNA also serves as a template for the synthesis of
negative RNAwhich is used to generatemore genome copies and
to transcribe the subgenomic 26S mRNA from an internal
promoter (Strauss and Strauss, 1994). The lytic cycle of SV
infection has two well-defined stages. In the first one, SV
genomic RNA is translated to render the non-structural proteins,
nsp1, 2, 3 and 4. These proteins are required for viral replication
and transcription (Kaariainen and Ahola, 2002). At about 2–4 h
post infection (h p.i.), the pattern of protein synthesis drastically
changes and subgenomic RNA translation increases notably,
while genomic RNA is encapsidated in new virus particles. In
vertebrate cells, a rapid inhibition of host protein synthesis
occurs at this time of infection (Frolov and Schlesinger, 1994,
1996; Strauss and Strauss, 1994; Ventoso et al., 2006). The
ability of a virus to inhibit the translation of cellular mRNAs
under conditions in which viral mRNAs are translated has been⁎ Corresponding author.
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doi:10.1016/j.virol.2007.02.001observed in mammalian and other higher eukaryotic cells for a
variety of positive- and negative-strand RNA viruses, including
poliovirus and influenza virus, and for many species of DNA
viruses such as adenoviruses, herpesviruses and poxviruses
(Bushell and Sarnow, 2002; Schneider and Mohr, 2003;
Thompson and Sarnow, 2000). How this blockade is accom-
plished remains still poorly understood in many cases, and
different viruses may use different mechanisms to achieve this
differential inhibition of translation (Bushell and Sarnow, 2002;
Schneider and Mohr, 2003; Thompson and Sarnow, 2000).
Brefeldin A (BFA) is a macrolide compound capable of
disrupting the vesicular system and blocking glycoprotein
secretion in eukaryotic cells (Klausner et al., 1992; Lee and
Linstedt, 1999; Nebenfuhr et al., 2002; Pelham, 1991; Sata et al.,
1999). The molecular target of BFA is a subset of Sec7-type
GTP-exchange factors (GEFs), which activate a GTP-binding
protein known as ADP-ribosylation factor 1 (ARF1) (Jackson
and Casanova, 2000). ARF1 recruits the COPI coat and AP-1/
clathrin coat protein complexes involved in the formation of
transport vesicles (Scales et al., 2000). BFA inhibits the GDP-
GTP-exchange reaction between GEF and ARF1, leading to the
inhibition of ARF activation (Jackson and Casanova, 2000;
Renault et al., 2003). As a consequence, coat proteins are
released fromGolgi membranes, provoking the loss of control of
fusion and budding membranes (Klausner et al., 1992; Kreis
Fig. 1. Effect of BFA on cellular and SV late protein synthesis. Mock-infected
(A) or SV-infected BHK cells (multiplicity of infection, 20 PFU/cell) (B) were
treated for 6 h and then labeled with [35S]-Met/Cys during 30 min in the
presence of the same concentrations of BFA. Samples were processed by SDS–
PAGE, fluorography and autoradiography as indicated in Materials and
methods. P160, precursor of SV structural proteins; PE2, precursor of E2
glycoprotein; E1, mature SV E1 glycoprotein. (C) SV C protein and a cellular
protein, both indicated with arrows, were subjected to densitometric analysis to
estimate the percentage of protein synthesis compared to untreated controls.
431S. Molina et al. / Virology 363 (2007) 430–436et al., 1995; Lippincott-Schwartz et al., 1990, 1991; Orci et al.,
1991; Pelham, 1991; Scales et al., 2000; Torii et al., 1995). BFA
possesses antiviral activity against enveloped viruses since it
impedes the maturation of viral glycoproteins and the production
of infectious particles which mature on the plasma membrane or
within the cell (Dasgupta and Wilson, 2001; Irurzun et al., 1993;
Madan et al., 2005; Mirazimi et al., 1996; Suikkanen et al.,
2003). The replication of viruses such as poliovirus or vesicular
stomatitis virus is inhibited by BFA since RNA replication of
these viruses requires continuous synthesis of lipids to provide
new membranes to which viral replication complexes attach.
Therefore, this compound acts against some non-enveloped
viruses, interfering with genome replication, which requires an
intact vesicular system (Cuconati et al., 1998; Gazina et al.,
2002; Irurzun et al., 1992, 1993; Maynell et al., 1992). BFA also
decreases protein synthesis in culture cells. Thus, BFA treatment
of rat GH3 pituitary cells leads to an inhibition of protein
synthesis at the initiation level (Fishman and Curran, 1992;
Mellor et al., 1994). Presumably, this effect is due to the stress
situation of the endoplasmic reticulum caused by the disorga-
nization of the membrane system (Liu and Kaufman, 2003;
Mellor et al., 1994; Prostko et al., 1993). We have now analyzed
the action of BFA on the translation of BHK-21 cells and SV-
infected cells and also tested the effect of BFA on SV mRNA
synthesis. Our results indicate that BFA delays viral translation
by retarding viral RNA synthesis.
Results
Effect of BFA on protein synthesis in BHK-21 and SV-infected
cells
To test the effect of BFA on protein synthesis, SV-infected or
uninfected BHK-21 cells were treated with different concentra-
tions of BFA after viral adsorption. Concentrations of BFA
ranged from 1 to 20 μg/ml. Cellular (Fig. 1A) and late viral
protein synthesis (Fig. 1B) were analyzed after 6 h of BFA
treatment by metabolic labeling with 35S-Met/Cys. At all the
concentrations analyzed, BFA induced an inhibition of cellular
protein synthesis of around 80%, whereas very little effect was
observed on viral translation. Notably, SV protein synthesis was
not inhibited at the highest concentration of BFA whereas
cellular translation was strongly blocked by only 1 μg/ml of this
antibiotic. The comparative activity of BFA on cellular and viral
protein synthesis is represented in Fig. 1C. There is a clear
differential inhibition caused by BFA on cellular as compared to
subgenomic SV mRNA translation.
Our next aim was to examine the action of BFA on the early
and late phases of the viral cycle. This was achieved by adding
BFA after virus adsorption or at 2 h p.i. and analyzing the
synthesis of structural viral proteins at 2, 4 and 6 h p.i. by
protein radiolabeling (Fig. 2A). As a control, translation in
untreated cells infected by SV, as well as in non-infected cells
(Fig. 2B), was estimated. Addition of BFA after viral adsorption
caused 91% inhibition of viral translation at 2 h p.i. This
inhibition decreased throughout the course of infection and was
only 10% at 6 h p.i. However, when BFAwas added at 2 h p.i.,the reduction in viral translation was about 39% at the begin-
ning of infection, and no differences in protein synthesis with
respect to the untreated cells were observed at 6 h p.i. Therefore,
BFA only delays but does not inhibit synthesis of SV structural
proteins.
In culture cells, such as rat GH3 pituitary cells, BFA
induces eIF2α phosphorylation, which could be responsible
for the inhibition of translation (Mellor et al., 1994). Therefore,
phosphorylation of eIF2α during BFA treatment and after SV
infection of BFA-treated or non-treated cells was analyzed
(Fig. 3). To avoid the potential inhibition of virus entry by
BFA, this compound was added after virus adsorption. Cells
were collected at the times indicated in the figure, and
phosphorylated or total eIF2 were detected by Western blotting
with specific antibodies. As a control, eIF2α phosphorylation
was estimated in mock-infected non-BFA-treated cells. In
BFA-treated cells, the phosphorylated form is detectable from
2 h of treatment, both in mock-infected and SV-infected cells,
while phosphorylation of eIF2α in SV-infected non-treated
cells was detected from 4 h p.i., as described previously (Ven-
toso et al., 2006). In addition, eIF2 remains phosphorylated at
4 and 6 h p.i. in SV-infected BFA-treated cells when SV tran-
slation reaches the levels of non-treated controls. This result
suggests that, although in SV-infected BFA-treated cells the
eIF2α phosphorylation was initially induced by BFA treat-
ment, it did not affect SV RNA translation. On the other hand,
inhibition of cellular protein synthesis can be observed after
2 h of treatment with BFA, which coincides with an increase in
the phosphorylated form of eIF2α.
Fig. 2. Kinetics of cellular and SV late protein synthesis: effect of BFA. (A) SV-
infected cells were treated at 0 or 2 h p.i. and radiolabeled at 2, 4 and 6 h p.i.
during 30 min. (B) Mock-infected cells were treated with BFA and radiolabeled
after 2, 4 or 6 h of treatment. In both cases, BFA was present during labeling.
Samples were processed by SDS–PAGE, followed by fluorography and
autoradiography. The numbers below each lane represent the percentage of
protein synthesis with respect to non-treated controls calculated by densitometry
of SV C protein and a cellular protein, indicated by the arrows. P160: precursor
of SV structural proteins; PE2, precursor of E2 glycoprotein; E1, mature SV E1
glycoprotein.
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genomic RNA, a recombinant virus SV-Luc with the luciferase
gene inserted into the nsp3 sequence was employed (Bick et al.,
2003). BHK cells were treated with 5 μg/ml of BFA at 2 h
before infection with SV-Luc, after virus adsorption, or at 2 h
post infection. Although in SV-infected cells, the synthesis of
non-structural proteins ceases at 4 h p.i., SV-luc has a delayed
early phase. For this reason, luciferase activity was measured at
2, 4 and 6 h p.i., the time when genomic RNA is being translated
(Ventoso et al., 2006). The greatest inhibition of luciferaseFig. 3. Phosphorylation of eIF2α. SV-infected or mock-infected cells were
treated with BFA, added after virus adsorption. After 2, 4 or 6 h, cells were
collected in sample buffer and subjected to SDS–PAGE andWestern blotting, as
described in Materials and methods, using specific antibodies for the
phosphorylated (eIF2-P) and the non-phosphorylated form of eIF2. As a
control, non-treated mock-infected BHK cells were used.synthesis occurred when cells were treated with BFA before
infection (Fig. 4A). When BFAwas present from the beginning
of infection or from 2 h p.i., luciferase synthesis was about 70%
as compared to the non-treated control at 4 h p.i., and no effect
was observed at 6 h p.i. These results indicate that the
expression of genomic and subgenomic mRNAs of SV is
delayed by BFA treatment. Interestingly, these data also suggest
that the inhibitory effect of BFA would not be correlated withFig. 4. Effect of BFA on SV non-structural proteins and RNA synthesis. SV-luc
infected cells were treated with 5 μg/ml of BFA 2 h before infection and at 0 and
2 h p.i. Cells were collected at 2, 4 and 6 h p i. to measure luciferase activity (A)
or the amount of luciferase, fused to nsP3 or as part of the nsPs polyprotein by
Western blot using a rabbit polyclonal antiserum (B), as described in Materials
and methods. (C) Quantitation of total RNA and genomic RNA (D) molecules in
SV-infected cells in the presence or absence of 5 μg/ml of BFA. BFAwas added
at 0 h p.i. and cells were collected at 2, 4 and 6 h p.i. RNA was extracted and
quantified by real-time PCR as described in Materials and methods. Data are
presented as percentages of number of molecules of RNA in BFA-treated with
respect to non-treated cells.
433S. Molina et al. / Virology 363 (2007) 430–436eIF2α phosphorylation since this phosphorylation inhibits
translation of SV genomic RNA (Ventoso et al., 2006). To
assay if BFA alters the proteolytic processing of early SV
proteins, BHK cells, untreated or treated with 5 μg/ml BFA for
2 h, were infected with SV-Luc. At 2, 4 and 6 h p.i., cells were
collected and the amount of luciferase fused with the nsP3, as
well as the uncleaved precursors, was detected by Western
blotting (Fig. 4B). The levels of unprocessed polyprotein were
undetectable in BFA-treated cells or proportional to those
detected in the non-treated control, indicating that this
compound does not affect the proteolytic cleavage of SV non-
structural proteins.
Effects of BFA on SV RNA synthesis
We next determined the effect of BFA on SV RNA synthesis.
In this experiment, SV-infected BHK cells were treated with
BFA immediately after infection, and at 2, 4 and 6 h p.i. RNA
was extracted and quantitated by real-time PCR, using specific
oligonucleotides for measuring total RNA (Fig. 4C) or genomic
RNA (Fig. 4D). The amount of total RNA in BFA-treated cells
was lower than in non-treated cells during the initial hours of
infection. However, at later times a similar amount of total RNA
was detected in BFA-treated and non-treated cells. These
findings suggest that SV replication is delayed by BFA, thus
accounting for the decreased synthesis of both structural and
non-structural proteins. Analysis of genomic RNA levels
revealed that they were lower in BFA-treated cells during the
entire treatment period, which suggests that BFA interferes with
SV RNA synthesis rather than protein synthesis.
Effect of BFA on viral replication
Since BFA blocks genome replication of some viruses
(Gazina et al., 2002; Irurzun et al., 1992, 1993; Maynell et al.,
1992), our next aim was to determine whether BFA inhibited
SV replication using the SV replicon repL26S C-luc (Fig. 5A).
BHK cells were treated for 4 h with 5 μg/ml BFA and then
electroporated with repL26S C-luc. BFA was maintained after
electroporation, and cells were collected at 2, 4 and 6 h p.e.
Luciferase activity, which reflects the level of proteins
translated from subgenomic mRNA, is shown in Fig. 5B. An
acute effect of BFA can be observed within the first hours of
electroporation, while at 6 h p.e. the luciferase activity is
similar to that found in untreated controls. In addition, the
effect of BFA on translation of the non-replicative RNAs 49S-
luc and L26SC-luc was assayed. A schematic representation of
these RNAs is shown in Fig. 5A. Both RNAs were
electroporated in BHK cells previously treated with BFA for
4 h. BFA was maintained during and after electroporation, andFig. 5. Effect of BFA on SV replication. (A) Schematic representation of the
different viral RNAs repL26S C-luc, L26SC-luc and 49S-luc. (B) Luciferase
activity at 2, 4 and 6 h p.e. of BHK cells with the replicative RNA repL26S C-luc,
in the presence or absence of BFA. (C) and (D) show the measurement of lucifera-
se activity at 2, 4 and 6 h p.e. in BHK cells electroporated with the non-replicative
RNAs L26SC-luc and 49S-luc, respectively, in the presence or absence of BFA.cells were collected at 2, 4 and 6 h p.e. to measure luciferase
activity (Figs. 5C and D). In both cases, luciferase activity in
BFA-treated cells was higher than in untreated control cells,
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of non-replicative RNAs. The lack of inhibition of SV 49S-
derived RNA by BFA is consistent with the results obtained
with the SV-Luc virus (Fig. 4A).
These findings suggest that BFA interferes with the SV
replicative RNA but does not inhibit the non-replicative forms,
supporting the idea that the action of BFA on SV is due to the
delay in RNA synthesis.
Discussion
The fungal metabolite BFA is a well characterized inhibitor
of the secretory pathway in mammalian cells (Lippincott-
Schwartz et al., 1991; Orci et al., 1991; Pelham, 1991). BFA
also causes a potent inhibition of cellular protein synthesis,
presumably due to the unfolded protein response (UPR)
triggered in the endoplasmic reticulum as a consequence of
disorganization of the membrane system (Fishman and Curran,
1992; Liu and Kaufman, 2003; Mellor et al., 1994; Prostko et
al., 1993). Notably, SV protein synthesis is maintained after a
prolonged treatment with this compound, thus reflecting a
differential behaviour between cellular and viral mRNAs.
Indeed, BFA strongly inhibits cellular protein synthesis,
whereas SV translation is only slightly delayed. Notably, the
amount of phosphorylated eIF2α increases after 2 h treatment of
BHK cells with BFA, in agreement with previous results
reported for GH3 pituitary cells (Mellor et al., 1994). This
finding can be interpreted as a consequence of UPR activation
(Dinter and Berger, 1998; Harding et al., 1999; Lee and
Linstedt, 1999). However, this phosphorylation might not be the
sole cause of translation inhibition induced by BFA since
cellular protein synthesis is not completely abrogated. Further-
more, the synthesis of luciferase from SV-Luc and the SV-
derived genomic RNA in BFA-treated cells is not inhibited, and
the translatability of exogenous viral mRNAs transfected in
BFA-treated cells was not affected (data not shown).
On the other hand, SV protein synthesis is reduced in the
presence of BFA only at early times after infection. Viral
translation recovers throughout the time of treatment, so that the
levels of SV protein synthesis reach those observed in untreated
infected cells. The inhibitory effect of BFA is lower when added
later during infection, suggesting that BFA has an indirect effect
on SV protein synthesis. Previous studies that analyzed the
action of BFA on togavirus protein synthesis added this
compound or analyzed protein synthesis at later times of
infection, thus, no effect of BFAwas observed on genomic nor
subgenomic RNA translation (Carleton and Brown, 1996; Da
Costa and Rebello, 1999; Madan et al., 2005). Interestingly, the
amount of genomic RNA is lower in the presence of BFA as
compared to untreated cells, indicating that BFA interferes with
viral RNA replication. This possibility is reinforced by the
observation that BFA only reduced the expression of the SV-
derived replicon, whereas non-replicative mRNAs were trans-
lated under these conditions. The finding that the 49S non-
replicative RNA is not inhibited by BFA treatment agrees with
the idea that the action of BFA on SV is exerted on replication.
The resistance of 26S mRNA to BFA, which increases eIF2αphosphorylation, could be due to its hairpin structures that may
provide translational resistance to the conditions induced by this
compound (Ventoso et al., 2006).
The action of BFA on the vesicular system impairs the
maturation of viral glycoproteins, suppressing the formation of
viral particles of enveloped viruses (Dasgupta andWilson, 2001;
Irurzun et al., 1993; Madan et al., 2005; Mirazimi et al., 1996;
Suikkanen et al., 2003). In addition, BFA also has an inhibitory
effect on replication of many non-enveloped viruses without
glycoproteins, such as enteroviruses and rhinoviruses. In these
cases, BFA abrogates viral replication since this process is
associated with the formation of vesicular structures (Cuconati
et al., 1998; Gazina et al., 2002; Irurzun et al., 1992; Maynell et
al., 1992). BFA is known to affect the control of fusion and
budding of membranes, and so also influences the process of
vacuole formation (Klausner et al., 1992; Kreis et al., 1995;
Lippincott-Schwartz et al., 1990, 1991; Orci et al., 1991;
Pelham, 1991; Scales et al., 2000; Torii et al., 1995). Replication
of SV alters intracellular membranes, creating new vesicles
which are linked to viral RNA synthesis (Kujala et al., 2001;
Peranen et al., 1995; Salonen et al., 2005). Most probably, BFA
interferes with the formation of the new vesicles by decreasing
the replication efficiency, and hence affecting viral protein
synthesis (Cuconati et al., 1998; Irurzun et al., 1992; Maynell
et al., 1992). This hypothesis also explains the differential effect
observed when BFA is added at different times after infection,
with the greatest effect when BFAwas present before infection.
When SV infection takes place in cells previously treated with
BFA, the vesicular system is disorganized before the replicative
complexes are formed. In this case, replication may be more
affected than when BFA is added after virus adsorption or at 2 h
p.i. The formation of the vesicles needed for viral replication
before BFA addition may result in a lower inhibition of replica-
tion. However, this inhibition is partial even when BFA is added
before infection. Thus, viral replication is not completely
abolished by the presence of BFA since RNA and protein
synthesis increases throughout infection. Therefore, BFA may
disturb and delay, but not completely block, the formation of
viral replication complexes. In such conditions, more time is
needed to reach adequate levels of SV non-structural proteins in
BFA-treated cells. Thus, the amount of viral RNA and protein
synthesis finally recovered in the presence of BFA and at 6 h p.i.
is comparable to non-treated controls.
Taken together, these results provide further insight into the
effect of the macrolide compound BFA on alphavirus infection.
Materials and methods
Cell culture and viruses
Baby hamster kidney (BHK-21) cells were grown at 37 °C
in Dulbecco's Modified Eagle's medium (DMEM) supplemen-
ted with 5% fetal calf serum (FCS) and non-essential amino
acids. Wild-type (wt) SV and SV-Luc stocks were obtained
from the cDNA clones pT7SVwt (Hahn et al., 1992; Sanz and
Carrasco, 2001) and pToto1101/Luc, respectively (generously
provided by Charles M. Rice, Rockefeller University, NY)
435S. Molina et al. / Virology 363 (2007) 430–436(Bick et al., 2003). They were propagated and titered in BHK-
21 cultures.
Plasmids
The replicon repL26S C-luc was obtained by in vitro
transcription from the plasmid pT7 repL26S C-luc. This plasmid
is derived from pT7SVwt and contains the luciferase gene
between the SV C protein sequence and the SV 3′ non-coding
region with deletion of the sequence encoding for E3, E2, 6K
and E1 proteins. The first three codons encoding for E3 are
maintained to facilitate the autoproteolytic cleavage of C protein.
The non-replicative RNA 49S-luc was obtained by in vitro
transcription from pToto1101/Luc digested with BssHII, which
eliminates the 3′ non-coding region. The resulting RNA was
polyadenylated post-transcriptionally with PolyA polymerase
(Invitrogen).
The non-replicative RNA L26SC-luc was obtained by in
vitro transcription from pT7 C+ Luc. This plasmid contains the
subgenomic sequence from repL26S C-luc after the T7 promoter
sequence, which permits the in vitro production of this mRNA.
Viral infections
BHK-21 cells were infected with wild-type SVor SV-Luc at
a multiplicity of infection of 10 PFU/cell. After 30 min of
adsorption, the medium was removed and culture plates were
incubated with fresh DMEM supplemented with 5% FCS.
Effects of different compounds on SV and cellular translation
BFA (5 μg/ml) (Sigma) was added to the SV-infected cultures
at different h p.i. At the indicated times, proteins were labeled for
30 min with 200 μl methionine/cysteine-free DMEM supple-
mented with 1 μl Trans label [35S]-Met/Cys (15 mCi/ml,
Amersham Biosciences) per well in the presence or absence of
the inhibitor. Cells were collected in sample buffer, boiled for
4 min and analyzed by SDS–PAGE and fluorography.
Western blot analysis
The phosphorylation state of the translation initiation factor
eIF2 was determined by Western blotting (Ventoso et al., 2006),
as well as the proteolytic cleavage of the nsPs. BHK-21 cells
were infected, treated with BFA or infected and treated with
BFA after virus adsorption. At different h p.i., cells were
collected in sample buffer and proteins were fractionated by
SDS–PAGE in 15% polyacrylamide gels and transferred to
nitrocellulose membranes by wet transfer. Membranes were
blocked with PBS containing 5% low-fat dry milk. Anti-eIF2
(Santa Cruz), anti-phosphorylated-eIF2 (Biosource) or anti-
Luciferase (Promega) antibodies were then added, and the
membranes were washed with PBS containing 0.2% Tween 20.
Goat anti-rabbit horseradish peroxidase-conjugated antibodies
(Pierce) and the ECL kit (Amersham Biosciences) were used to
detect bound antibodies. Chemiluminescence was detected by
exposure to Agfa X-ray film.Measurement of luciferase activity
BHK-21 cells were infected with SV-Luc or electroporated
with 20 μg of RNA. At different hours post-electroporation (h p.
e.), cells were lysed in a buffer containing 0.5% Triton X-100,
25 mM glycylglycine (pH 7.8) and 1 mM dithiothreitol.
Luciferase activity was determined using a Monolight 2010
apparatus (Analytical Luminescence Laboratory), as described
previously (Ventoso and Carrasco, 1995).
Analysis of mRNA by real-time PCR
SV RNA levels in infected cells were determined by real-
time quantitative reverse transcription (RT)-PCR as previously
described (Alvarez et al., 2003; Castello et al., 2006). Briefly,
total RNAwas extracted from 25×10 cells at the times indicated
in each figure, using the RNeasy commercial kit (Qiagen)
following the manufacturer's recommendations. The isolated
RNAwas resuspended in 30 μl of nuclease-free water, and 3 μl
was subjected to analysis. Real-time quantitative RT-PCR was
performed with the LightCycler thermal cycler system (Roche
Diagnostics) using the RNA Master SYBR Green I kit (Roche
Diagnostics) as described (Alvarez et al., 2003; Castello et al.,
2006). The primers C-forward (5′-GAA CGA GGA CG GAGA
TGT CAT CG-3′) and C-reverse (5′-CAG CGC CAC CGA
GGA CTATCG C-3′) were employed to quantify the total SV
RNA. Data analysis was done using the Roche Molecular
Biochemicals LightCycler software, version 3.3. The specificity
of the amplification reactions was confirmed by analyzing the
corresponding melting curves.
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